TG Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	531.9	329	233.66	2.79	6.69	0.15
Revenue Growth (YoY)	100.88%	40.80%	8290.02%	-58.36%	4300.66%	-
Cost of Revenue	77.97	38.49	14.13	0.27	0.79	-
Gross Profit	453.93	290.52	219.53	2.52	5.9	0.15
Selling, General & Admin	208.25	154.3	122.71	95.48	128.09	107.85
Research & Development	142.9	94.29	76.19	125.35	222.58	165.9
Operating Expenses	351.15	248.59	198.9	220.84	350.67	273.75
Operating Income	102.78	41.93	20.63	-218.32	-344.77	-273.59
Interest Expense	-27.26	-24.03	-12.62	-10.19	-5.64	-6.33
Other Non Operating Income (Expenses)	12.23	7.69	5.04	4.7	2.31	0.54
Pretax Income	87.75	25.59	13.06	-223.81	-348.1	-279.38
Income Tax Expense	-359.72	2.21	0.39	-	-	-
Net Income	447.47	23.38	12.67	-223.81	-348.1	-279.38
Net Income to Common	447.47	23.38	12.67	-223.81	-348.1	-279.38
Net Income Growth	-	84.52%	-	-	-	-
Shares Outstanding (Basic)	146	145	142	135	132	115
Shares Outstanding (Diluted)	162	160	149	135	132	115
Shares Change (YoY)	11.64%	7.96%	9.67%	2.41%	14.64%	30.51%
EPS (Basic)	3.06	0.16	0.09	-1.65	-2.63	-2.42
EPS (Diluted)	2.78	0.15	0.09	-1.65	-2.63	-2.42
EPS Growth	-	68.03%	-	-	-	-
Free Cash Flow	-70.24	-40.56	-31.41	-176.18	-296.04	-214.86
Free Cash Flow Per Share	-0.43	-0.25	-0.21	-1.30	-2.24	-1.86
Gross Margin	85.34%	88.30%	93.95%	90.48%	88.19%	100.00%
Operating Margin	19.32%	12.74%	8.83%	-7838.99%	-5154.28%	-179996.05%
Profit Margin	84.13%	7.11%	5.42%	-8036.34%	-5204.08%	-183803.29%
Free Cash Flow Margin	-13.21%	-12.33%	-13.44%	-6326.18%	-4425.70%	-141357.90%
EBITDA	102.83	42	20.84	-218.01	-344.49	-273.44
EBITDA Margin	19.33%	12.77%	8.92%	-	-	-
D&A For EBITDA	0.05	0.07	0.21	0.3	0.28	0.16
EBIT	102.78	41.93	20.63	-218.32	-344.77	-273.59
EBIT Margin	19.32%	12.74%	8.83%	-	-	-
Effective Tax Rate	-	8.64%	2.99%	-	-	-
Revenue as Reported	531.9	329	233.66	2.79	6.69	0.15

Updated Nov 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q